Adding spironolactone to an ACE inhibitor or angiotensin II receptor blocker (ARB) is associated with a marked and sustained antiproteinuric effect in type 2 diabetics, researchers in the Netherlands found.

KIDNEY DISEASE linked to diabetes, hypertension, and obesity is increasing throughout the world. It is estimated that diabetes leading to end-stage renal disease (ESRD) accounts for 40% of the patients who require kidney transplants in the United States, Europe, Japan, Australia, and New Zealand.

RENAL HYPERTROPHY is a major factor in the development of diabetic nephropathy in patients with type 1 diabetes.

Patients with diabetic nephropathy who are candidates for kidney or kidney- pancreas transplantation should be screened routinely with coronary angiography, researchers in Norway conclude.

Eli Lilly and Company has received an approvable letter from the FDA requesting additional supporting data for its new drug application for ruboxistaurin mesylate (proposed trade name: Arxxant), Lilly's investigational oral therapy for diabetic retinopathy.